Research map: Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year

Back to the article

Papers in this map

  1. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes · Juhani M. Knuuti · 2019 · 7290 citations · Cited by this paper
  2. Predictors of Outcomes in Patients With Clinically Suspected Myocarditis: Analysis From a Single Center Registry · 2026 · Related
  3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients · 2002 · 6990 citations · Cited by this paper
  4. Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications · 2026 · Related
  5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) · 1996 · 6561 citations · Cited by this paper
  6. Exploration of the Pathogenesis and Treatment of Heart Failure · 2026 · Related
  7. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation · The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators · 2001 · 6517 citations · Cited by this paper
  8. Potential Relationship Between Ferroptosis and Pyroptosis in Myocardial Ischemia/Reperfusion Injury: Molecular Mechanisms and Therapeutic Targets · 2026 · Related
  9. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation · Jean‐Philippe Collet · 2020 · 5139 citations · Cited by this paper
  10. Cost Impact of a Coronary Computed Tomography Angiography-Based Diagnostic Pathway for Low-Risk Chest Pain in the Emergency Department · 2026 · Related
  11. 2024 ESC Guidelines for the management of chronic coronary syndromes · Christiaan J. Vrints · 2024 · 2786 citations · Cited by this paper
  12. Reframing Benign Prostatic Hyperplasia as a Cardiometabolic Condition: Should BPH Be Considered a Metabolic Disease? · 2026 · Related
  13. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease · John W. Eikelboom · 2017 · 2459 citations · Cited by this paper
  14. Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies · 2026 · Related
  15. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction · Marc P. Bonaca · 2015 · 2003 citations · Cited by this paper
  16. Poor Distal Left Atrial Appendage Opacification on Early-Phase Cardiac CTA and Association With Arterial Thromboembolism · 2026 · Related
  17. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents · Laura Mauri · 2014 · 1929 citations · Cited by this paper
  18. Pericardial Diseases in Cardiovascular Medicine: Contemporary Diagnosis, Risk Stratification, Multimodality Imaging, and Targeted Anti-Inflammatory Therapy · 2026 · Related
  19. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation · Renato D. Lópes · 2019 · 1225 citations · Cited by this paper
  20. Prophylactic Methylprednisolone in Neonatal On-Pump Cardiac Surgery · 2026 · Related
  21. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials · Francesco Costa · 2017 · 1190 citations · Cited by this paper
  22. Rivaroxaban in Peripheral Artery Disease after Revascularization · Marc P. Bonaca · 2020 · 1034 citations · Cited by this paper
  23. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update · Stuart A. Scott · 2013 · 975 citations · Cited by this paper
  24. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting · Jean‐Philippe Collet · 2012 · 885 citations · Cited by this paper
  25. A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI · Daniel M.F. Claassens · 2019 · 654 citations · Cited by this paper
  26. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk · Philip M. Urban · 2019 · 621 citations · Cited by this paper
  27. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease · Satoshi Yasuda · 2019 · 570 citations · Cited by this paper
  28. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention · Naveen L. Pereira · 2020 · 422 citations · Cited by this paper
  29. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis · Marco Valgimigli · 2025 · 93 citations · Cited by this paper
  30. Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention · Felice Gragnano · 2024 · 91 citations · Cited by this paper
  31. P2Y 12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials · Daniele Giacoppo · 2025 · 48 citations · Cited by this paper
  32. Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized Trials · Felice Gragnano · 2026 · 10 citations · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)